World Federation of Societies of Biological Psychiatry (WFSBP) consensus statement on candidate biomarkers for anorexia nervosa

Read full text
Authors: Hubertus Himmerich, Johanna Louise Keeler, Joseph A. King, Stefan K. Ehrlich, Lisa-Katrin Kaufmann, Cynthia M Bulik, Sarah Cohen‐Woods, Tracey Wade, Howard Steiger, Linda Booij, Palmiero Monteleone, Giammarco Cascino
+43 more Alessio Maria Monteleone, Ulrich Cuntz, Ulrich Voderholzer, Selamawit Alemayehu Tessema, Yael Doreen Lewis, Magnus Sjögren, Johannes Hebebrand, Jochen Seitz, Marta Tyszkiewicz‐Nwafor, Olga Karpenko, Hiba Mutwalli, Sergueï O. Fetissov, Isabelle Mack, Namrata Dhopatkar, Sabrina Mörkl, Carol Kan, Maria Mercedes Uribe, Kazuhiro Yoshiuchi, Nadine Abuobeid, Dimitrios Kapogiannis, Daniel Stein, Sevgi Bektas, Daniel J. Müller, P. Gorwood, Philibert Duriez, Chloé Tezenas du Montcel, Elżbieta Paszyńska, Susan L McElroy, Wiesława Dominika Wranik, Fernando Fernandez-Aranda, Philip S. Mehler, Hana Papežová, Radka Roubalová, Petra Procházková, Rebecca H. Morris, Piotr Lewczuk, Christoph Hiemke, Michael Berk, Andreas Karwautz, Janet Treasure, S. Kasper, the WFSBP Task Force on Biological Markers, the WFSBP Task Force on Eating Disorders
Cited by: 14
References: 718

Abstract

OBJECTIVES: This World Federation of Societies of Biological Psychiatry (WFSBP) consensus paper aims to summarise and evaluate the published study results on objectively measurable biological markers associated with anorexia nervosa (AN). METHODS: The relevant literature was reviewed by the WFSBP Task Forces on Eating Disorders and on Biological Markers, and a consensus regarding the significance of the published evidence was reached. RESULTS: Candidate biological markers that have been associated with AN include clinical (e.g. body weight), molecular (e.g. genetic, epigenetic, hormonal, immunological, metabolomic), cellular (e.g. leukocytes), neuroimaging (e.g. structure, function, connectivity), digital, cardiac and neurophysiological parameters. Some clinical and laboratory parameters are risk markers in clinical practice. Biological markers have pathophysiological relevance in understanding the biological and metabolic pathophysiology of AN and its physical health consequences. Few studies have examined pharmacogenetics or therapeutic drug monitoring as tools to monitor and guide the treatment of AN. CONCLUSIONS: Biological markers will hopefully soon enable clinicians to intervene earlier in a more targeted manner to mitigate treatment resistance. However, the current scientific basis for most biological markers are group comparisons only. Studies on sensitivity, specificity and the prognostic value of these markers are lacking.

Fields of Study & Subjects

Eating Disorders and Behaviors Body Image and Dysmorphia Studies Autism Spectrum Disorder Research

Publication details

Journal / source
The World Journal of Biological Psychiatry
Publisher
Informa UK Limited
Volume
27
Issue
4
Pages
257–348
Publication date
1 March 2026
Language
EN